학술논문
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease
Document Type
Article
Author
Source
In Clinical Lung Cancer January 2017 18(1):68-76
Subject
Language
ISSN
1525-7304